Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Cyclophosphamide Generic Name & Formulations
Legal Class
Rx
General Description
Cyclophosphamide 25mg, 50mg; tabs.
Pharmacological Class
Alkylating agent.
See Also
How Supplied
Contact supplier
Manufacturer
Cyclophosphamide Indications
Indications
Carcinoma of the breast.
Cyclophosphamide Dosage and Administration
Adult
Initial and maintenance: 1–5mg/kg/day.
Children
See full labeling.
Cyclophosphamide Contraindications
Contraindications
Severe bone marrow depression.
Cyclophosphamide Boxed Warnings
Not Applicable
Cyclophosphamide Warnings/Precautions
Warnings/Precautions
Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Cyclophosphamide Pharmacokinetics
See Literature
Cyclophosphamide Interactions
Interactions
Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.
Cyclophosphamide Adverse Reactions
Adverse Reactions
GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.
Cyclophosphamide Clinical Trials
See Literature
Cyclophosphamide Note
Notes
Formerly known under the brand name Cytoxan.
Cyclophosphamide Patient Counseling
See Literature
Cyclophosphamide Generic Name & Formulations
Legal Class
Rx
General Description
Cyclophosphamide 25mg, 50mg; tabs.
Pharmacological Class
Alkylating agent.
See Also
How Supplied
Contact supplier
Manufacturer
Cyclophosphamide Indications
Indications
Neuroblastoma (disseminated disease).
Cyclophosphamide Dosage and Administration
Adult
Initial and maintenance: 1–5mg/kg/day.
Children
See full labeling.
Cyclophosphamide Contraindications
Contraindications
Severe bone marrow depression.
Cyclophosphamide Boxed Warnings
Not Applicable
Cyclophosphamide Warnings/Precautions
Warnings/Precautions
Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Cyclophosphamide Pharmacokinetics
See Literature
Cyclophosphamide Interactions
Interactions
Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.
Cyclophosphamide Adverse Reactions
Adverse Reactions
GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.
Cyclophosphamide Clinical Trials
See Literature
Cyclophosphamide Note
Notes
Formerly known under the brand name Cytoxan.
Cyclophosphamide Patient Counseling
See Literature
Cyclophosphamide Generic Name & Formulations
Legal Class
Rx
General Description
Cyclophosphamide 25mg, 50mg; tabs.
Pharmacological Class
Alkylating agent.
See Also
How Supplied
Contact supplier
Manufacturer
Cyclophosphamide Indications
Indications
Retinoblastoma.
Cyclophosphamide Dosage and Administration
Adult
Initial and maintenance: 1–5mg/kg/day.
Children
See full labeling.
Cyclophosphamide Contraindications
Contraindications
Severe bone marrow depression.
Cyclophosphamide Boxed Warnings
Not Applicable
Cyclophosphamide Warnings/Precautions
Warnings/Precautions
Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Cyclophosphamide Pharmacokinetics
See Literature
Cyclophosphamide Interactions
Interactions
Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.
Cyclophosphamide Adverse Reactions
Adverse Reactions
GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.
Cyclophosphamide Clinical Trials
See Literature
Cyclophosphamide Note
Notes
Formerly known under the brand name Cytoxan.
Cyclophosphamide Patient Counseling
See Literature
Cyclophosphamide Generic Name & Formulations
Legal Class
Rx
General Description
Cyclophosphamide 25mg, 50mg; tabs.
Pharmacological Class
Alkylating agent.
See Also
How Supplied
Contact supplier
Manufacturer
Cyclophosphamide Indications
Indications
Adenocarcinoma of the ovary.
Cyclophosphamide Dosage and Administration
Adult
Initial and maintenance: 1–5mg/kg/day.
Children
See full labeling.
Cyclophosphamide Contraindications
Contraindications
Severe bone marrow depression.
Cyclophosphamide Boxed Warnings
Not Applicable
Cyclophosphamide Warnings/Precautions
Warnings/Precautions
Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Cyclophosphamide Pharmacokinetics
See Literature
Cyclophosphamide Interactions
Interactions
Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.
Cyclophosphamide Adverse Reactions
Adverse Reactions
GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.
Cyclophosphamide Clinical Trials
See Literature
Cyclophosphamide Note
Notes
Formerly known under the brand name Cytoxan.
Cyclophosphamide Patient Counseling
See Literature
Cyclophosphamide Generic Name & Formulations
Legal Class
Rx
General Description
Cyclophosphamide 25mg, 50mg; tabs.
Pharmacological Class
Alkylating agent.
See Also
How Supplied
Contact supplier
Manufacturer
Cyclophosphamide Indications
Indications
Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma. Multiple myeloma. Leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease).
Cyclophosphamide Dosage and Administration
Adult
Initial and maintenance: 1–5mg/kg/day.
Children
See full labeling.
Cyclophosphamide Contraindications
Contraindications
Severe bone marrow depression.
Cyclophosphamide Boxed Warnings
Not Applicable
Cyclophosphamide Warnings/Precautions
Warnings/Precautions
Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Cyclophosphamide Pharmacokinetics
See Literature
Cyclophosphamide Interactions
Interactions
Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.
Cyclophosphamide Adverse Reactions
Adverse Reactions
GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.
Cyclophosphamide Clinical Trials
See Literature
Cyclophosphamide Note
Notes
Formerly known under the brand name Cytoxan.
Cyclophosphamide Patient Counseling
See Literature
